Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial
- 1 April 2019
- journal article
- research article
- Published by Elsevier in Kidney International
- Vol. 95 (4) , 973-982
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- A Longitudinal Study of Left Ventricular Function and Structure from CKD to ESRDClinical Journal of the American Society of Nephrology, 2013
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialThe Lancet, 2011
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- Effect of Spironolactone on Left Ventricular Systolic and Diastolic Function in Patients With Early Stage Chronic Kidney DiseaseThe American Journal of Cardiology, 2010
- A Randomized, Double-Blind, Placebo-Controlled Trial of Spironolactone on Carotid Intima-Media Thickness in Nondiabetic Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2010
- Rosuvastatin and Cardiovascular Events in Patients Undergoing HemodialysisNew England Journal of Medicine, 2009
- Left Ventricular Filling Pressure by Doppler Echocardiography in Patients With End-Stage Renal DiseaseHypertension, 2008
- Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 2003
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Reduced capillary density in the myocardium of uremic rats—A stereological studyKidney International, 1992